Jonathan Jonisch, MD
Ophthalmology · Great Neck, NYNPI 1467613216
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $499,278 of the $725,717 with a category attached, or 68.8%. 20 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 41.3% of the total. Among ophthalmology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 666 payments — averaging $1089.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$300K
- Apellis Pharmaceuticals, Inc.$245K
- Genentech USA, Inc.$105K
- Novartis$52K
- Coherus Oncology, Inc.$8K
- Harrow Eye, LLC$6K
- plus $10K from 14 others
Across 29 payments — averaging $10,073 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$252K
- Janssen Research & Development, LLC$40K
What the payments were for
- Consulting fees$162,93122%
- Speaking & faculty fees$499,27869%
- Travel & lodging$39,7045%
- Food & beverage$23,8053%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 247 | $299,689 |
| Apellis Pharmaceuticals, Inc. | 182 | $245,167 |
| Genentech USA, Inc. | 135 | $104,919 |
| Novartis | 41 | $52,249 |
| Coherus Oncology, Inc. | 10 | $7,936 |
| Harrow Eye, LLC | 4 | $5,803 |
| Genentech, Inc. | 6 | $4,799 |
| Regeneron | 3 | $3,408 |
| Astellas Pharma US Inc | 13 | $607 |
| AbbVie(2 entities) | 12 | $232 |
| Alcon | 2 | $228 |
| Cardinal Health 110 LLC | 1 | $150 |
| Tarsus Pharmaceuticals, Inc. | 1 | $124 |
| Kala Pharmaceuticals, Inc. | 1 | $119 |
| Glaukos Corporation | 1 | $71 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $71 |
| Alimera Sciences, Inc. | 3 | $70 |
| Sandoz | 1 | $33 |
| Bausch & Lomb Americas Inc. | 1 | $24 |
| Biogen | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$725,717 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 90 | $4,383 |
| Difluprednate | 22 | $2,548 |
| Ofloxacin | 71 | $1,102 |
| Ketorolac Tromethamine | 28 | $1,036 |
| Latanoprost | 25 | $321 |
| Timolol Maleate | 13 | $81 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Great Neck
- Philip FerroneGreat Neck$155K
- David RubaltelliBrooklyn$8.9M
- Nathan RadcliffeNew York$2.1M
- Richard SpaideNew York$1.7M
- Eric DonnenfeldGarden City$1.4M
- Marguerite McDonaldOceanside$893K
- Joshua YoungNew York$814K
- David KleinmanRochester$730K
- Joseph PanarelliNew York$541K
- Eric RosenbergNew York$434K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.